Maha Radhakrishnan

CIK: 0002013423

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CADL

Candel Therapeutics, Inc.

Director

TRDA

Entrada Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

CADL
Candel Therapeutics, Inc.
Jun 23, 2026
Award(A)
Stock Option (Right to Buy)
Direct
32K shares-
TRDA
Entrada Therapeutics, Inc.
Jun 10, 2026
Award(A)
Stock Option (Right to Buy)
Direct
19K shares-
CADL
Candel Therapeutics, Inc.
Jun 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
28.5K shares-
TRDA
Entrada Therapeutics, Inc.
Jun 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
38K shares-

		Type	Shares	Price		Ownership
Jun 23, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	32,000	-	-	Direct
Jun 10, 2026	TRDA Entrada Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,000	-	-	Direct
Jun 4, 2025	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	28,480	-	-	Direct
Jun 1, 2025	TRDA Entrada Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	38,000	-	-	Direct

1-4 of 4 transactions

About Radhakrishnan Maha

Radhakrishnan Maha (SEC CIK 0002013423) files insider reports with the SEC as Director of Candel Therapeutics, Inc. (CADL) and Director of Entrada Therapeutics, Inc. (TRDA).

Signal8 holds 6 ownership filings by Radhakrishnan Maha (2 Form 3, 4 Form 4), filed between Jun 3, 2025 and Jun 24, 2026. Those filings report 4 transactions, from Jun 1, 2025 to Jun 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Radhakrishnan Maha's filings is in BOSTON, MA.

Recent filings by Radhakrishnan Maha

Jun 23, 2026: Grant or award of CADL derivative securities (Form 4, code A).
Jun 10, 2026: Grant or award of TRDA derivative securities (Form 4, code A).
Jun 4, 2025: Grant or award of CADL derivative securities (Form 4, code A).
Jun 1, 2025: Grant or award of TRDA derivative securities (Form 4, code A).

Other insiders filing for Candel Therapeutics, Inc. (CADL)

Loggia Nicoletta, Director
PAPA JOSEPH C, Director
Manning Paul B, Director
Tak Paul Peter, Chief Executive Officer
Zimmermann Martine, Director
Tyagarajan Seshu, Chief Technology Officer

How to read Form 4 transaction codes